The panel will discuss a unique perspective on the opportunities for biotech companies to treat cardiometabolic disease and obesity.

Details on the presentation are as follows:

Panel: Cardiometabolic Disease & Obesity: Unlocking Unique Partnering Opportunities for Biotech

Date: Monday, April 29, 2024

Time: 2:00 – 2:40 p.m. GMT

Location: Business Design Centre

About Aphaia Pharma

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. APH-012 is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.


Aphaia Investor Contact
Günter Jucho
Chief Financial Officer

Media Contact
Madelin Hawtin
LifeSci Communications